Status:

WITHDRAWN

Prediction of NEC With Urinary iFABP

Lead Sponsor:

Loma Linda University

Conditions:

Prematurity

Necrotizing Enterocolitis

Eligibility:

All Genders

Up to 2 years

Phase:

PHASE2

Brief Summary

During the first four days of life, intestinal fatty acid binding protein (iFABP) is elevated in the urine of premature babies who go on to develop necrotizing enterocolitis (NEC) days to weeks later....

Detailed Description

Necrotizing enterocolits (NEC) occurs with an incidence of 3-7% in very low birth weight (\<1500g) infants and is associated with significant morbidity and mortality. Earlier detection of a subclinica...

Eligibility Criteria

Inclusion

  • Gestational age less than 33 weeks
  • Admission to Loma Linda University Children's Hospital NICU within 48 hours of life

Exclusion

  • Anuria
  • Congenital gastrointestinal anomaly

Key Trial Info

Start Date :

November 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2016

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01805206

Start Date

November 1 2014

End Date

July 1 2016

Last Update

May 14 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Loma Linda University Children's Hospital

Loma Linda, California, United States, 92354